In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Another pivotal study, published in 2022 in the New England Journal of Medicine, found that tirzepatide helped people with overweight or obesity lose an average of 21 percent of their body weight ...

Zepbound, made by Eli Lilly, is the brand name for tirzepatide when used for weight loss. When the drug is prescribed for diabetes, it is sold under the brand name Mounjaro. Image ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

However, tirzepatide was more likely to help participants achieve major weight-loss milestones. Nearly one-third (32%) of participants experienced a 25% or more body weight reduction due to ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with menopause hormone therapy. A Mayo Clinic study revealed that this dual ...

Zepbound (tirzepatide) is a prescription weight loss medicine. It contains tirzepatide, the same active ingredient as the type 2 diabetes medicine Mounjaro. The FDA approved Zepbound in 2023 to ...

New research compared the effect of semaglutide vs. tirzepatide on weight loss over a 72 week period. Here's what the study found, and what a doctor has to say about it.

Key Takeaways Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action. Semaglutide has the longest half-life of the three, which may ...